AMIX earnings analysis
What we found in AMIX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Autonomix remains a development-stage company with no reported revenue, segment revenue, gross margin, operating margin, or EPS in the provided filing text. Cost control improved, with operating expenses down 19% year over year to $2.77 million, but operating cash use increased to $3.5 million and the company had only $3.5 million of cash at June 30, 2026. Management expects runway only into the first quarter of 2027 and estimates a $25 million to $30 million financing requirement, while clinical enrollment remains paused and material control weaknesses persist.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Operating expenses declined 19%
- Total operating expenses declined 19% year over year to $2.77 million for the three months ended June 30, 2026, from $3.421 million. R&D decreased 5% to $1.515 million and G&A fell 31% to $1.255 million.
- Lower G&A improved cost discipline
- The $0.573 million reduction in G&A was driven primarily by a $0.3 million decrease in stock-based compensation, a $0.1 million reduction in legal and professional fees, and a $0.1 million decline in employee compensation and benefits.
- Warrant exercise added $2.6 million
- The July 2026 warrant exercise generated approximately $2.6 million of gross proceeds from the exercise of 428,731 Common Warrants at a reduced $6.00 exercise price, before fees and expenses.
- Bid-price compliance was restored
- The company regained compliance with Nasdaq's Bid Price Rule after its stock closed at or above $1.00 for 10 consecutive business days from June 24 through July 8, 2026.
- Cash position and capex remained contained
- Management reported $3.5 million of cash and $3.1 million of working capital as of June 30, 2026, with no cash used in investing activities during the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Significant financing need and limited runway
- Management said current cash resources of $3.5 million are sufficient only into, but not beyond, the first calendar quarter of 2027. It estimates that an additional $25 million to $30 million of financing will be required to fund operations through commercialization.
- Operating cash burn exceeds available funding
- Net cash used in operating activities was $3.5 million in the quarter ended June 30, 2026, up from $2.6 million in the prior-year quarter, while cash provided by financing activities was $0. The company stated that failure to raise sufficient capital could require it to scale back operations.
- Clinical enrollment pause raises execution risk
- The company observed variability in early clinical outcomes, which it believes may relate to vascular access and anatomical targeting, and subsequently paused enrollment for further evaluation and refinement. R&D expense remained $1.515 million for the quarter.
- Material weaknesses remain unresolved
- Disclosure controls and procedures were ineffective as of June 30, 2026. Management cited material weaknesses involving segregation of duties, general technology controls, and financial statement reporting.
- New Nasdaq MVLS delisting risk
- A newly adopted Nasdaq MVLS rule would require listed companies to maintain at least $5.0 million of market value of listed securities; a level below $5 million for 30 consecutive business days could result in immediate trading suspension. The rule was automatically stayed on July 29, 2026, pending SEC review.
- Warrant issuance creates dilution risk
- The July warrant inducement issued 428,731 Series D-1 warrants and 428,731 Series D-2 warrants, each with a 5.5-year term and a $5.75 exercise price, creating potential future dilution to existing shareholders.
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management stated that cash resources are sufficient to fund operations into, but not beyond, the first calendar quarter of 2027, and estimated additional financing needs of approximately $25 million to $30 million to reach commercialization.
The filing reads worse than the one before it.
What came before.
- 10-K · June 15, 2026
- Autonomix Medical, Inc. continues to struggle as a clinical-stage medical device company, highlighting significant operational challenges and an alarming accumulated deficit of $67.1 million with no revenue generation.…
- 10-K · May 27, 2026
- Autonomix Medical, Inc. reported significant operational challenges as a clinical-stage medical device company with an accumulated deficit of $67.1 million and no revenues. The company faces substantial doubt about its…
- 10-Q · February 11, 2026
- Autonomix remains a pre-revenue, clinical‑stage company. For the quarter ended December 31, 2025 the company reported a net loss of $3,261 thousand (loss per share $(0.36)), higher operating expenses driven by R&D of…
- 10-Q · August 13, 2025
- Autonomix remains a pre-revenue clinical-stage company. For the quarter ended June 30, 2025 the company reported a net loss of $3.337 million (loss per share $1.07) on zero revenue, financed near-term operations with…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing AMIX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever